Chinese Innovative Drugs Gain Momentum with Multiple FDA Fast Track Designations in 2025

　　【Pharmaceutical Network Product InformationOn the evening of May 19, XenoPharm announced that SYS6010 (CPO301), a drug developed by its subsidiary CSPC Innovation, had recently been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced or metastatic non-squamous non-small cell lung cancer (Nsq-NSCLC) who do not have epidermal growth factor receptor mutations or other driver gene alterations (AGA), and whose disease has progressed after previous platinum-based chemotherapy and anti-PD-(L)1 therapy. After receiving Fast Track designation, the company will have more opportunities to communicate with the U.S. FDA during the subsequent drug development and review process.
 

Data shows that SYS6010 (CPO301) is an antibody-drug conjugate (ADC) targeting EGFR tumor-associated antigens. It has received clinical trial approval in both China and the United States, and relevant clinical trials are currently underway. This marks the third Fast Track designation granted to the drug by the U.S. FDA.
 

The U.S. FDA granted the aforementioned drug Fast Track designation, which will accelerate its clinical development and approval process, potentially bringing it to market more quickly and providing patients with a new treatment option.
 

In fact, since the beginning of this year, multiple drugs in China have been granted Fast Track designation by the FDA. For example, on May 19, CSPC announced that its first-in-class Epidermal Growth Factor Receptor (EGFR) Antibody-Drug Conjugate (ADC), CPO301, had received a third Fast Track designation from the FDA for the treatment of adult patients with advanced or metastatic non-squamous non-small cell lung cancer who do not have EGFR mutations or other driver gene alterations and whose disease has progressed after previous treatment with platinum-based chemotherapy and anti-PD-(L)1 antibody therapy.
 

On the same day, September 19, Zai Lab announced that its first-in-class potential Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC) ZL-1310 received Fast Track designation from the FDA for the treatment of extensive-stage small cell lung cancer.
 

In early May, Qilu Pharmaceutical's QLS1304 tablet was granted Fast Track Designation (FTD) by the FDA. This project's product is a small molecule targeted inhibitor with high activity, good selectivity, and excellent oral bioavailability, which is expected to reshape the treatment landscape for ER+/HER2- breast cancer. On April 27th, just prior to this, the drug had received clinical trial authorization by default from the U.S. FDA and is intended for the treatment of ER+/HER2- breast cancer.
 

On March 17, 2025, U.S. time, SGC001, an acute myocardial infarction antibody drug developed by Beijing Shunjing Biomedical Technology Co., Ltd., an innovative pharmaceutical company incubated by Hotgen Biotech, was granted Fast Track designation by the FDA. As a monoclonal antibody candidate for emergency use, SGC001 is specifically designed for the urgent treatment of patients with acute myocardial infarction and is currently in clinical research involving such patients. Completed clinical trials in healthy individuals have demonstrated its good safety and tolerability. The granting of FDA Fast Track designation will further accelerate the commercialization process of SGC001 and provide a more effective treatment option for patients with acute myocardial infarction.
 

In March 2025, Shanghai Rongrui Pharmaceutical Technology Co., Ltd.'s self-developed oncolytic virus Class I new drug OVV-01 Vesicular Stomatitis Virus Injection received the FDA's Fast Track designation for Phase II clinical trials to treat advanced soft tissue sarcoma. Previously, OVV-01 Vesicular Stomatitis Virus Injection was granted Investigational New Drug (IND) approval by the U.S. Food and Drug Administration (FDA) for both Phase II and Phase I clinical trials, becoming the first oncolytic virus product in China to receive two IND approvals from the U.S. FDA simultaneously. This Fast Track designation granted by the FDA will significantly accelerate the development process of this product during the clinical trial period.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.